Ligand Pharmaceuticals Incorporated

NasdaqGM:LGND Rapport sur les actions

Capitalisation boursière : US$2.3b

Ligand Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Le PDG Ligand Pharmaceuticals est Todd Davis, nommé en Dec2022, a un mandat de 1.92 ans. La rémunération annuelle totale est $ 6.22M, composée du salaire de 10.5% et des bonus 89.5%, y compris les actions et options de la société. détient directement 0.42% des actions de la société, d'une valeur de $ 9.44M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2 ans et 15 ans.

Informations clés

Todd Davis

Directeur général

US$6.2m

Rémunération totale

Pourcentage du salaire du PDG10.5%
Durée du mandat du directeur général1.9yrs
Propriété du PDG0.4%
Durée moyenne d'occupation des postes de direction2yrs
Durée moyenne du mandat des membres du conseil d'administration15yrs

Mises à jour récentes de la gestion

Recent updates

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Nov 24

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Oct 31
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 18
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29
Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23
Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Apr 30

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Dec 19
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

Jun 14
Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

May 29
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07
Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27
Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Analyse de la rémunération des PDG

Comment la rémunération de Todd Davis a-t-elle évolué par rapport aux bénéfices de Ligand Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

US$45m

Jun 30 2024n/an/a

US$42m

Mar 31 2024n/an/a

US$96m

Dec 31 2023US$6mUS$650k

US$54m

Sep 30 2023n/an/a

US$21m

Jun 30 2023n/an/a

US$41m

Mar 31 2023n/an/a

US$51m

Dec 31 2022US$6mUS$49k

-US$5m

Sep 30 2022n/an/a

US$23m

Jun 30 2022n/an/a

US$27m

Mar 31 2022n/an/a

US$45m

Dec 31 2021US$328kn/a

US$76m

Sep 30 2021n/an/a

US$68m

Jun 30 2021n/an/a

US$48m

Mar 31 2021n/an/a

US$39m

Dec 31 2020US$329kn/a

US$7m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$350kn/a

US$629m

Sep 30 2019n/an/a

US$594m

Jun 30 2019n/an/a

US$677m

Mar 31 2019n/an/a

US$764m

Dec 31 2018US$343kn/a

US$143m

Sep 30 2018n/an/a

US$179m

Jun 30 2018n/an/a

US$120m

Mar 31 2018n/an/a

US$53m

Dec 31 2017US$283kn/a

US$13m

Rémunération vs marché: La rémunération totale de Todd ($USD 6.22M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 5.50M ).

Rémunération et revenus: La rémunération de Todd a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Todd Davis (63 yo)

1.9yrs

Titularisation

US$6,216,518

Compensation

Mr. Todd C. Davis, Ph.D. is a Director at NVN Liquidation Inc. He serves as an Independent Director of Channel Therapeutics Corporation (formerly known as Chromocell Therapeutics Corporation) since January...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Todd Davis
CEO & Director1.9yrsUS$6.22m0.42%
$ 9.4m
Octavio Espinoza
Chief Financial Officer2yrsUS$2.45m0.13%
$ 2.9m
Andrew Reardon
Chief Legal Officer & Secretary2yrsUS$2.34m0.12%
$ 2.7m
Paul Hadden
Senior Vice President of Investments & Business Developmentno datapas de donnéespas de données
Michael Jeong
Head of Investor Relationsno datapas de donnéespas de données
Todd Pettingill
Director of Corporate Developmentno datapas de donnéespas de données
Keith Marschke
Senior Vice President of Biology & Scientific Affairs6.8yrspas de donnéespas de données
Vincent Antle
Senior Vice President of Technical Operations & QA - Capitsol6.8yrspas de donnéespas de données
Patrick Lucy
Senior VP & CBO Protein Expression Businessno datapas de donnéespas de données
Karen Reeves
Senior VP of Investments & Head of Clinical Strategyless than a yearpas de donnéespas de données
Richard Baxter
Senior VP of Investment Operationless than a yearpas de donnéespas de données
Scott Plesha
CEO of Pelthos Therapeuticsless than a yearpas de donnéespas de données

2.0yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe de direction de LGND n'est pas considérée comme expérimentée (ancienneté moyenne 2 ans), ce qui suggère une nouvelle équipe.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Todd Davis
CEO & Director17.7yrsUS$6.22m0.42%
$ 9.4m
John Kozarich
Independent Chairman21.7yrsUS$361.70k0.23%
$ 5.1m
John LaMattina
Independent Director13.8yrsUS$329.20k0.15%
$ 3.4m
Stephen Sabba
Independent Director16.3yrsUS$341.70k0.15%
$ 3.4m
Jason Aryeh
Independent Director18.2yrsUS$339.20k0.43%
$ 9.8m
Shalendar Bhasin
Scientific Advisorno datapas de donnéespas de données
Jason Haas
Independent Director2.4yrsUS$346.70k0.022%
$ 494.1k
Nancy Gray
Independent Director7.3yrsUS$336.70k0.030%
$ 671.4k
Martine Zimmermann
Independent Director1.2yrsUS$467.87kpas de données

15.0yrs

Durée moyenne de l'emploi

63.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la LGND est chevronné et expérimenté ( 15 années d'ancienneté moyenne).